The patent covers the method of treating human diseases or disorders using PI3K and HDAC proteins, including but not restricted to CUDC-907.
Designed to inhibit PI3K-alpha, delta and beta isoforms and HDACs 1, 2, 3, 6 and 10, the combined inhibition of CUDC-907 is supposed to have synergistic effects against cancer cells and their microenvironment.
Curis chief executive officer Dan Passeri said, "We believe that this patent issuance significantly bolsters the intellectual property protection for Curis’ proprietary dual targeted inhibitory molecules, including CUDC-907, a molecule that was invented by Curis scientists and is currently in Phase I clinical testing in patients with relapsed or refractory lymphomas or multiple myeloma."
The company is planning to advance the ongoing Phase I study and initiate additional studies with CUDC-907 in solid tumors later in 2013.